Between January and April 3, 2026, the Russian State Center for Quality and Standardization of Veterinary Drugs and Feed (VGNKI) conducted four inspections of foreign manufacturing sites for compliance with Good Manufacturing Practice (GMP) requirements. The checks took place in China, Serbia, France, and New Zealand. This is reported by the institution’s press service.
Geography and Scope of Inspections
The inspections were carried out at facilities producing injectable and oral solutions, suspensions, chewable tablets, and powders. The profile of the inspected sites covered various therapeutic areas:
- In China, the inspection covered the production of a drug for treating osteoarthritis in dogs.
- In Serbia, experts evaluated a site manufacturing antibacterial and urological medicines for food-producing and companion animals.
- In France, the check was conducted at a plant producing antibacterial and antiparasitic drugs for cattle, sheep, and pigs, as well as products for preventing anemia in piglets.
- In New Zealand, the inspection took place at a facility producing drugs for the prevention of ketosis in dairy cows.
Inspection Objectives
The checks were initiated by the foreign manufacturers. The primary goal of the inspections is to introduce new veterinary drugs to the Russian market. Currently, reports on the results of the GMP inspections are in the finalization stage.
